3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Lung Neoplasms
2
Pulmonary Disease, Chronic Obstructive
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Multiple Myeloma
1
Leukemia, Plasma Cell
1
Leukemia
1
Graft vs Host Disease
1
Carcinoma, Non-Small-Cell Lung
1
Asthma
1
Interventions
fludarabine phosphate
9
fludarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Cyclophosphamide
7
Mycophenolic Acid
6
Lenalidomide
6
Dexamethasone
6
Tacrolimus
5
Bortezomib
4
Sirolimus
3
ixazomib
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
daratumumab
2
auricularum
2
Stem Cell Transplantation
2
Etoposide
2
Cytarabine
2
Cyclosporine
2
Carmustine
2
Calcium Dobesilate
2
Antilymphocyte Serum
2
Allopurinol
2
talquetamab
1
sargramostim
1
pomalidomide
1
montanide ISA 51
1
merphos
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Plasma Cell
×
Budesonide
×
Clear all
NCT05405387
2026-06-05
IMPACT
University of Utah
Phase 2
Recruiting
120 enrolled